ACADIA Pharmaceuticals Inc.
ACAD
$27.44
$0.893.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.69% | 14.41% | 22.42% | 31.85% | 47.06% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.69% | 14.41% | 22.42% | 31.85% | 47.06% |
| Cost of Revenue | 23.67% | -6.46% | -0.98% | -2.08% | -10.24% |
| Gross Profit | 6.14% | 34.19% | 45.61% | 71.89% | 137.46% |
| SG&A Expenses | 11.40% | 20.45% | 22.62% | 20.14% | 17.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.61% | 7.02% | 10.94% | 9.21% | 3.91% |
| Operating Income | -15.88% | 295.77% | 2,027.13% | 214.85% | 172.70% |
| Income Before Tax | 100.21% | 485.61% | 1,676.93% | 605.67% | 203.85% |
| Income Tax Expenses | 52.63% | 201.21% | 116.49% | 208.53% | -52.34% |
| Earnings from Continuing Operations | 103.24% | 626.84% | 13,484.97% | 469.50% | 186.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 103.24% | 626.84% | 13,484.97% | 469.50% | 186.36% |
| EBIT | -15.88% | 295.77% | 2,027.13% | 214.85% | 172.70% |
| EBITDA | -12.91% | 203.34% | 1,575.15% | 247.67% | 183.04% |
| EPS Basic | 100.76% | 627.33% | 11,962.07% | 461.27% | 185.19% |
| Normalized Basic EPS | -4.78% | 197.32% | 1,110.05% | 294.86% | 195.91% |
| EPS Diluted | 100.61% | 660.79% | 7,291.58% | 448.69% | 183.42% |
| Normalized Diluted EPS | -4.85% | 202.07% | 1,197.95% | 292.56% | 195.28% |
| Average Basic Shares Outstanding | 1.34% | 1.18% | 1.15% | 1.24% | 1.41% |
| Average Diluted Shares Outstanding | 1.23% | 0.86% | 0.65% | 1.16% | 1.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |